Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers

• Status: Completed
• Trial end date: 2018-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Comparing the structural effects of TNFi and tocilizumab on the periarticular bone by performing a comprehensive analysis of the periarticular bone changes in RA patients treated with either TNFi or tocilizumab in a longitudinal Setting, using high-resolution peripheral quantitative computed tomography (HR-pQCT), a very sensitive method for visualizing and quantifying bone microstructure in RA patients. Quantitatively assessing the changes of erosions volume, osteophytes size and the area of cortical fenestration in a group of TNFi-treated and a group of tocilizumab- treated RA patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Adalimumab; Certolizumab Pegol; Etanercept; Golimumab; Infliximab

Criteria

Inclusion Criteria:

• Females and males with RA erosions in the wrist and/or MCP joints

• Must be aged ≥ 18 years at time of consent

• Stable treatment with conventional DMARDs of at least 3 months

Exclusion Criteria:

• Patients exposed to abatacept or rituximab in the last 12 months

• Patients receiving glucocorticoids over 5 mg prednisolone per day

• Patients who are younger than 18 years

• Pregnant or lactating females

• Patients having received an HR-pQCT examination during the last 6 months before screening